Kai Xu

机构：Tongji University, China Pharmaceutical University, Nanjing Traditional Chinese Medicine Hospital, Second Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital, Nanjing Medical University · ORCID：0009-0000-6503-2490

发表论文 7 篇 · 总被引 74 次 · h-index 4

代表论文

• UCP2 −866G/A and Ala55Val, and UCP3 −55C/T polymorphisms in association with type 2 diabetes susceptibility: a meta-analysis study (2011 · Diabetologia · 被引 39)
• Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China (2024 · International Journal of Clinical Pharmacy · 被引 16)
• Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis (2025 · Annals of Medicine · 被引 12)
• Expression of RUNX3 gene in pancreatic adenocarcinoma and its clinical significance (2014 · Genetics and Molecular Research · 被引 4)
• TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma (2025 · Cell Death and Disease · 被引 2)
• Economics, efficacy and safety of five traditional Chinese medicine injections plus chemotherapy as adjuvant therapy for non-small cell lung cancer: A network meta-analysis (2025 · International Journal of Clinical Pharmacy · 被引 1)